

Appendix D: Evidence tables

Table D1: Study characteristics of included articles

Author,Year Trial	Planned length of follow-up (months)	Study design	Device type Device name	Funding source
CARE-HF Main Trial- Cleland,2004 ¹ Sub Studies- Cleland,2006 ² Cleland,2007 ³ Cleland,2009 ⁴ Cleland,2012 ⁵ Ghio,2009 ⁶ Gras,2007 ⁷ Wikstrom,2009 ⁸	18	RCT	CRT-P Medtronic InSync or InSync III device	Industry
MADIT CRT Main Trial- Moss,2009 ⁹ Sub Studies- Arshad,2011 ¹⁰ Barsheshet,2011 ¹¹ Goldenberg,2011 ¹² Goldenberg,2014 ¹³ Hsu,2012 ¹⁴ Jamerson,2014 ¹⁵ Ouellet,2012 ¹⁶ Penn, 2010 ¹⁷ Ruwald,2014 ¹⁸ Solomon,2010 ¹⁹ Tompkins,2013 ²⁰ Zareba,2011, ²¹	36	RCT	CRT-D Boston Scientific	Industry
RAFT Main Trial- Tang,2010 ²² Sub Studies- Birnie,2013 ²³ Gilis,2014 ²⁴ Healey,2012 ²⁵	NR	RCT	CRT-D Commercially available transvenous leads and devices (Medtronic)	Funded by the Canadian Institutes of Health Research and Medtronic of Canada
MIRACLE ICD Main Trial- Young,2003 ²⁶	6	RCT	CRT-D InSync Model 8040, Medtronic	Industry
MIRACLE Main Trial- Abraham,2002 ²⁷ Sub Study- Sutton,2003 ²⁸	6	RCT	CRT-P InSync Model 8040, Medtronic	Industry

Author,Year Trial	Planned length of follow-up (months)	Study design	Device type Device name	Funding source
COMPANION Main Trial- Bristow,2004 ²⁹ Sub Studies- Anand, 2009 ³⁰ Carson,2005 ³¹	2 years; median follow-up varied for each group (11.9 months arm 1; 16.2 months arm 2; 15.7 months arm 3)	RCT	CRT-P and D Pacemakers were Contak TR model 1241, Guidant; CRT-D was Contac CD model 1823, Guidant)	Industry
MUSTIC Main Trial- Cazeau,2001 ³² Sub Study- Leclercq,2002 ³³	6	RCT	CRT-P Chorum 7336 MSP, ELA Medical, Montrouge, France, and InSync 8040, Medtronic	Industry
Abraham,2004 ³⁴ MIRACLE ICD II Trial	6	RCT	CRT-D Model 7272 InSync ICD, Medtronic, Inc Industry	NR
SMART AV Sub Studies- Cheng, 2012 ³⁵ Gold,2011 ³⁶		RCT	CRT-P NR	Industry
MASCOT Sub Study- Schuchert,2013 ³⁷	12	RCT	CRT-P and D Frontierw or Frontierw II CRT-P or Epicw HF or Atlasw HF CRT-D	Industry St. Jude Medical
Diab, 2011 ³⁸	6	RCT	CRT-D NR	Unclear, some investigators receive funds, but not wholly funded study
Garikipati,2014 ³⁹	12	RCT	CRT-P NR	NR
Higgins,2003 ⁴⁰ VENTAK CHF/CONTAK CD	6	RCT	CRT-D Industry	NR
Lozano,2000 ⁴¹	3	RCT	CRT-P NR	NR
Pinter,2009 ⁴²	6	RCT	CRT-D CONTAK CD CHF Device, model no.	Industry

Author,Year Trial	Planned length of follow-up (months)	Study design	Device type Device name	Funding source
			1,823, or CONTAK RENEWAL HF Device, model no. H135	
Pokushalov,2010 ⁴³	18	RCT	CRT-P InSync III® CRT-P NA	NR
Leclercq,2007 ⁴⁴ RD-CHF Study	6	Randomiz ed cross over	CRT-P NR	NR
Auricchio,2014 ⁴⁵ CLEPSYDRA Sub Study-	13	Prospectiv e cohort	CRT-D Paradym™ RF CRT-D	Industry
Azizi, 2006 ⁴⁶	1.7 +/- 1.3 years	Retrospec tive cohort	CRT-P and D Tripos DR, Stratos, Chorus MSP, Talent MSP, Contak TR.TR2, Insync 8040, Insync III, Frontier, Vitatron, Tupos, Koronos, Renewal, Insync ICD, Insync Marquis, Sentry, Atlas, Epic	NR
Bilchick, 2010 ⁴⁷	NR	Retrospec tive cohort	CRT-D NR	Government
Bossard,2014 ⁴⁸	NR	Retrospec tive cohort	CRT-D NR	No Funding
Boven,2013 ⁴⁹	NR	Retrospec tive cohort	CRT-D NR	NR
Boven,2013 ⁵⁰	NR	Retrospec tive cohort	CRT-P and D Medtronic Inc.,Minneapolis, MN, USA or Boston Scientific Inc., Indianapolis, IN, USA	NR
Cock, 2003 ⁵¹	2-3	Prospectiv e cohort	CRT-P Medtronic LDS, Biotronik SCOUT	NR
Duray,2008 ⁵²	6	Prospectiv e cohort	CRT-D NR	Other-specify No external financial support
Gasparini,2009 ⁵³ RELEVANT Study	NR	Prospectiv e cohort	CRT-D Medtronic InSync III Protect device and InSync III Marquis, InSync Maximo, InSync Sentry, Medtronic Inc., Minneapolis, MN, USA	Industry
Gopalamurugan,2014 ⁵⁴	NA	Retrospec tive cohort	CRT-D NR	NR
Gras,2002 ⁵⁵	12	Prospectiv e cohort	CRT-P	Industry

Author,Year Trial	Planned length of follow-up (months)	Study design	Device type Device name	Funding source
			InSync model 8040	
Haugaa,2014 ⁵⁶	24	Prospectiv e cohort	CRT-D NR	NR
Hong-xia,2006 ⁵⁷	NR	Prospectiv e cohort	CRT-P Impulse generator: Insync 8040, Insync III 8042(Medtronic, USA). LV lead: 2188, 2187, 4189, 4191,4193 (Medtronic, USA)	NR
Killu,2011 ⁵⁸	NR	Retrospec tive cohort	CRT-P and D NR	NR
Knight,2004 ⁵⁹	9	Prospectiv e cohort	CRT-D NR	NR
Krahn,2002 ⁶⁰	NR	Prospectiv e cohort	CRT-P InSync model 8040, 7272, 8042	Non-profit
Kuhlkamp, 2002 ⁶¹	Median: 185 days	Prospectiv e cohort	CRT-D InSync 7272 ICD	Industry
Landolina,2011 ⁶²	NR	Prospectiv e cohort	CRT-D NR	Industry
Leong,2013 ⁶³	6	Prospectiv e cohort	CRT-P and D Contak Renewal,Contak TR or Contak CD (Guidant USA), Insync Marquis,Insync III, Insync Sentry or Protecta (Medtronic Inc. USA), AtlasHF (St Jude Medical USA) and Lumax (Biotronik, Germany)	Government
Mascioli,2012 ⁶⁴	NR	Prospectiv e cohort	CRT-D NR	NR
Masoudi,2014 ⁶⁵	NA	Retrospec tive cohort	CRT-D NR	Government
Mortensen,2004 ⁶⁶	6	Prospectiv e cohort	CRT-P InSync III® CRT-P	NR
Nian-Sang,2010 ⁶⁷	NR	Retrospec tive cohort	CRT-D NR	NR
Niebauer,2014 ⁶⁸	NA	Retrospec tive cohort	CRT-D NR	NR
Ricci,2014 ⁶⁹	NR	Prospectiv e cohort	CRT-D Medtronic CRT-ICD	Industry
Rickard,2013 ⁷⁰	NR	Retrospec	CRT-P and D	NR

Author,Year Trial	Planned length of follow-up (months)	Study design	Device type Device name	Funding source
		tive cohort	NR	
Romeyer- Bouchard,2010 ⁷¹	NR	Prospectiv e cohort	CRT-P and D NR	NR
Shanks,2011 ⁷²	6	Prospectiv e cohort	CRT-P Contak Renewal 4RF, TR, or CD [Boston Scientific, St Paul, MN]; InSync Sentry or III [Medtronic Inc, Minneapolis, MN]; or Lumax 340 HF- T [Biotronik, Berlin, Germany]	Industry
Shen,2009 ⁷³	NR	Retrospec tive cohort	CRT-D NR	NR
Shen,2009 ⁷⁴	NR	Retrospec tive cohort	CRT-P NR	NR
Shen,2011 ⁷⁵	NR	Retrospec tive cohort	CRT-P and D NR	NR
Stabile, 2009 ⁷⁶	Death	Prospectiv e cohort	CRT-P and D NR	NR
Stahlberg,2005 ⁷⁷	36	Prospectiv e cohort	CRT-P InSync,Thera,Kappa,Chorum,Talent, Frontier,Affinity	NR
Strimel, 2011 ⁷⁸	34 (mean)	Retrospec tive cohort	CRT-D NR	NR
Swindle,2010 ⁷⁹	NR	Retrospec tive cohort	CRT-P and D NR	Government
Takaya,2014 ⁸⁰	6	Prospectiv e Cohort	NR	None
Theuns,2005 ⁸¹	NR	Prospectiv e cohort	CRT-D InSync 7272 and 7279 (Medtronic Inc., Minneapolis, MN,USA), Contak CD, Renewal I, and Renewal II (GuidantInc., St. Paul, MN, USA), and Epic HF	NR
Vado,2014 ⁸²	NR	Prospectiv e cohort	CRT-D NR	NR
Verbrugge,2013 ⁸³	NA	Retrospec tive cohort	CRT-P and D NR	No Funding
Verbrugge,2013 ⁸⁴	NR	Prospectiv e cohort	CRT-P and D NR	Industry

Author,Year Trial	Planned length of follow-up (months)	Study design	Device type Device name	Funding source
Wollmann,2014 ⁸⁵	NR	Controlled trial, non- randomize d	CRT-D Protecta® CRT-D	Industry
Zhang, 2009 ⁸⁶	3	Prospectiv e cohort	CRT-P NR	NR

CRT-P=Cardiac Resynchronization Therapy Paced,CRT-D= Cardiac Resynchronization Therapy with Defibrillator,NR=Not Reported